Chelliah Selvam

Prof. Chelliah Selvam

Department of Pharmaceutical and Environmental Health Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
CGChandki Ram Gautam
Chandki Ram Gautam
CSChelliah Selvam
Chelliah Selvam
Synthesis methods for the exfoliation of BNNSs and BNNS functionalization methods are reviewed.

1 December 2019 in Life Sciences
Verified
Journal Article
Closed access
CSChelliah Selvam
Chelliah Selvam
SPSakthivel Lakshmana Prabu
Sakthivel Lakshmana Prabu
BJBrian C. Jordan
Brian C. Jordan
YPYasodha Purushothaman
Yasodha Purushothaman
AUAppavoo Umamaheswari
Appavoo Umamaheswari
RTRamasamy Thilagavathi
Ramasamy Thilagavathi

5 April 2017 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
CSChelliah Selvam
Chelliah Selvam
DMDaniel Mutisya
Daniel Mutisya
SPSandhya Prakash
Sandhya Prakash
KRKasturi Ranganna
Kasturi Ranganna
RTRamasamy Thilagavathi
Ramasamy Thilagavathi

1 March 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
KGKumararaja Gayathri
Kumararaja Gayathri
MBMahendran Bhaskaran
Mahendran Bhaskaran
CSChelliah Selvam
Chelliah Selvam
RTRamasamy Thilagavathi
Ramasamy Thilagavathi

1 January 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MHMaryam Sadat Hosseini-Zare
Maryam Sadat Hosseini-Zare
MSMozhgan Sarhadi
Mozhgan Sarhadi
MZMehdi Zarei
Mehdi Zarei
RTRamasamy Thilagavathi
Ramasamy Thilagavathi
CSChelliah Selvam
Chelliah Selvam

2 September 2015 in RSC Advances
Verified
Journal Article
Closed access
PDF file
CMCharlotta D. Mock
Charlotta D. Mock
BJBrian C. Jordan
Brian C. Jordan
CSChelliah Selvam
Chelliah Selvam
More than 230 000 diagnosed cases of invasive breast cancer in women were estimated in 2014 and an expected 40 000 deaths attributed to the aggressive carcinoma. An effective approach to diminish the morbidity and mortality of breast cancer is the development of chemopreventive and chemotherapeutic agents. Nutraceuticals have demonstrated their ability to proficiently halt carcinogenesis. The administration of natural compounds able to effectively serve as chemoprevention and chemotherapeutics without causing harm or adverse effects is imperative. Curcumin derived from the rhizome of Curcuma longa L., is a common spice of India, used for centuries because of its medicinal properties. The main component of curcumin possesses a wide range of biological activities; anti-proliferative, anti-inflammatory, and apoptotic characteristics modulated through the inactivation of pathways such as EGK and Akt/mTOR. In addition, curcumin alters the expression of cytokines, transcription factors, and enzymes involved in cell vitality. The in vivo application of curcumin in breast cancer is hindered by its limited bioavailabiity. The synthesis of curcumin analogues and delivery via nanoparticles has demonstrated enhanced bioavailability of curcumin in the malignancy. This review focuses on recent developments in the use of curcumin, curcumin analogues, and novel delivery systems as a preventive and therapeutic method for breast cancer.